Recode Therapeutics
Clinical trials sponsored by Recode Therapeutics, explained in plain language.
-
Experimental drug aims to clear lungs in rare genetic disease
Disease control CompletedThis early-stage study tested an experimental drug called RCT1100 in 14 adults with primary ciliary dyskinesia (PCD) caused by a specific genetic change in the DNAI1 gene. The goal was to see if the drug could improve how the lungs clear mucus and to check for safety. The results…
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental Gene-Targeting drug shows promise for rare lung disease
Disease control CompletedThis early-stage study tested a new drug called RCT1100 in 7 adults with primary ciliary dyskinesia (PCD) due to DNAI1 gene mutations. The main goal was to check safety and tolerability, while also looking for signs that the drug might help restore cilia function. Participants ha…
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New study sheds light on rare lung disease in adults
Knowledge-focused CompletedThis study observed 31 adults with primary ciliary dyskinesia (PCD) and healthy volunteers to measure lung function, mucus clearance, and quality of life. Researchers aimed to establish normal values and better understand how PCD affects the airways over time. No treatment was gi…
Sponsor: ReCode Therapeutics • Aim: Knowledge-focused
Last updated May 17, 2026 08:00 UTC